Source Paper
Prepulse Inhibition Deficits and Perseverative Motor Patterns in Dopamine Transporter Knock-Out Mice: Differential Effects of D1 and D2 Receptor Antagonists
Rebecca J. Ralph, Martin P. Paulus, Fabio Fumagalli, Marc G. Caron, Mark A. Geyer
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Baseline behavioral assessment
Assess baseline prepulse inhibition of startle response, locomotor patterns, and activity levels in DAT (-/-) mice and DAT (+/+) control mice
Note: DAT (-/-) mice exhibited deficient sensorimotor gating, nonfocal perseverative locomotion patterns, and hyperactivity compared to controls
View evidence from paper
“At baseline, DAT (-/-) mice exhibited deficient sensorimotor gating as measured by prepulse inhibition (PPI) of the startle response, exhibited nonfocal perseverative patterns of locomotion, and were hyperactive in a novel environment”
Pretreatment with D2 receptor antagonist
Administer raclopride as a pretreatment to DAT (-/-) mice
Note: Raclopride is a preferential dopamine D2 receptor antagonist
View evidence from paper
“Pretreatment with raclopride significantly increased PPI in the DAT (-/-) mice”
Measure PPI following D2 antagonist treatment
Assess prepulse inhibition of startle response following raclopride pretreatment
Note: Raclopride significantly increased PPI in DAT (-/-) mice
View evidence from paper
“Pretreatment with raclopride significantly increased PPI in the DAT (-/-) mice”
Pretreatment with D1 receptor antagonist
Administer SCH23390 as a pretreatment to DAT (-/-) mice
Note: SCH23390 is a D1 receptor antagonist
View evidence from paper
“challenging them with the preferential dopamine D2 receptor antagonist raclopride and D1 receptor antagonist SCH23390”
Measure PPI following D1 antagonist treatment
Assess prepulse inhibition of startle response following SCH23390 pretreatment
Note: SCH23390 had no significant effect on PPI in DAT (-/-) mice
View evidence from paper
“SCH23390 had no significant effect”
Assess motor behavior patterns following D2 antagonist
Evaluate locomotor patterns and motor behavior following raclopride treatment
Note: D2 receptor blockade did not affect the predominantly straight perseverative patterns of motor behavior
View evidence from paper
“Blockade of D2 receptors did not affect the predominantly straight patterns of motor behavior produced by the DAT (-/-) mice”
Assess motor behavior patterns following D1 antagonist
Evaluate locomotor patterns and motor behavior following SCH23390 treatment
Note: D1 receptor antagonism significantly attenuated perseverative patterns, producing more meandering behavior similar to wild-type controls
View evidence from paper
“antagonism of D1 receptors significantly attenuated the perseverative patterns, producing more of a meandering behavior seen in the DAT (+/+) control mice”
Measure activity levels following antagonist treatments
Assess hyperactivity levels in DAT (-/-) mice following both D1 and D2 receptor antagonist treatments
Note: Both D1 and D2 receptor antagonists decreased hyperactivity in DAT (-/-) mice
View evidence from paper
“Both D1 and D2 receptor antagonists decreased the hyperactivity seen in the DAT (-/-) mice”